Flexion Therapeutics, Inc. (FLXN) Stock Rating Reaffirmed by Northland Securities
Northland Securities reissued their buy rating on shares of Flexion Therapeutics, Inc. (NASDAQ:FLXN) in a research note published on Friday morning. They currently have a $40.00 price objective on the specialty pharmaceutical company’s stock.
A number of other equities analysts have also weighed in on FLXN. Zacks Investment Research lowered shares of Flexion Therapeutics from a hold rating to a sell rating in a research report on Thursday, July 13th. Royal Bank Of Canada reissued an outperform rating and issued a $44.00 price objective on shares of Flexion Therapeutics in a research report on Thursday, August 10th. Needham & Company LLC reissued a buy rating and issued a $36.00 price objective (up previously from $34.00) on shares of Flexion Therapeutics in a research report on Thursday, August 10th. BMO Capital Markets reissued a buy rating on shares of Flexion Therapeutics in a research report on Friday, August 11th. Finally, ValuEngine raised shares of Flexion Therapeutics from a sell rating to a hold rating in a research report on Friday, September 1st. One analyst has rated the stock with a sell rating, two have given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Flexion Therapeutics currently has an average rating of Buy and a consensus price target of $98.33.
Flexion Therapeutics (NASDAQ:FLXN) opened at $23.48 on Friday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 12.93 and a current ratio of 12.93. Flexion Therapeutics has a 52-week low of $15.96 and a 52-week high of $32.25.
TRADEMARK VIOLATION NOTICE: This article was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.watchlistnews.com/flexion-therapeutics-inc-flxn-stock-rating-reaffirmed-by-northland-securities/1701882.html.
In other Flexion Therapeutics news, insider Michael D. Clayman acquired 5,000 shares of the firm’s stock in a transaction on Wednesday, November 8th. The stock was bought at an average cost of $23.60 per share, for a total transaction of $118,000.00. Following the completion of the purchase, the insider now directly owns 35,395 shares in the company, valued at $835,322. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Yamo Deniz acquired 1,375 shares of the firm’s stock in a transaction on Thursday, August 31st. The shares were acquired at an average price of $25.40 per share, with a total value of $34,925.00. Following the completion of the purchase, the insider now owns 5,000 shares of the company’s stock, valued at $127,000. The disclosure for this purchase can be found here. Insiders have purchased 10,375 shares of company stock valued at $249,575 in the last ninety days. 15.98% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Fiduciary Trust Co. purchased a new stake in Flexion Therapeutics during the second quarter worth approximately $101,000. IFP Advisors Inc grew its stake in Flexion Therapeutics by 24.5% during the second quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock worth $103,000 after buying an additional 1,000 shares during the period. Advisor Group Inc. grew its stake in Flexion Therapeutics by 205.9% during the second quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock worth $105,000 after buying an additional 3,500 shares during the period. SG Americas Securities LLC purchased a new stake in Flexion Therapeutics during the third quarter worth approximately $135,000. Finally, State Board of Administration of Florida Retirement System purchased a new stake in Flexion Therapeutics during the third quarter worth approximately $235,000. Institutional investors own 69.17% of the company’s stock.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.